Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05459818
Other study ID # 2022-2052
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date October 12, 2022
Est. completion date July 2024

Study information

Verified date November 2023
Source Rijnstate Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the effectiveness of the VSX device in pre-determined patient populations to understand the patient characteristics that impact outcomes.


Description:

Rationale: Studies on the efficacy of self-expanding covered stents for the treatment of patients with superficial femoral artery (SFA) occlusive disease have mainly focused on stent patency. Subgroup analysis was often not feasible, related to small sample sizes. This pooled analysis of individual patient-level data provides larger sample sizes and a more heterogeneous population, which allows for the ability to perform subgroup analyses to identify patients that will most benefit from VSX treatment. The current analysis will provide insights into the effectiveness of the VSX device for specific subgroups. Objective: To evaluate the effectiveness of the VSX device in pre-determined patient populations to understand the patient characteristics that impact outcomes. Study design: Multicenter retrospective individual patient data meta-analysis. Study population: Patients treated with a VSX device for de novo or restenotic lesions of the superficial femoral artery and previously enrolled in a prospective VSX study whom were treated for SFA disease with the latest generation heparin-bonded Viabahn, and published in peer reviewed journals. Main study parameters/endpoints: The primary study parameter is primary patency at 12-months. In addition, for all subjects and for subgroups as described further below, the following secondary endpoints will be evaluated through follow-up: primary patency at 24 months, primary assisted patency, secondary patency, freedom from Target Lesion Revascularization (TLR) at 12 and 24 months, clinical Improvement, minor and major amputation, mortality. The following subgroup analysis will be performed if sufficient data are available: critical limb threatening ischemia patients (Rutherford 4-6), patients with intermittent claudication (Rutherford 1-3), chronic total occlusions, by gender, by number of runoff vessels, lesion length, TASC II lesion classification, calcified lesions, by device diameter.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 1000
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Patient was enrolled and treated with the GOREĀ® VIABAHNĀ® Endoprosthesis with Heparin Bioactive Surface device in a Gore-sponsored or physician-sponsored study for de novo or restenotic lesions of the femoropopliteal artery. 2. Lesions =10 cm in length and TASC C or D classification will be included 3. Patient-level data can be obtained and pooled with other studies Exclusion Criteria: 1. Patient was not formally enrolled in their corresponding study (e.g., training cases) 2. Patient was enrolled for treatment of in-stent restenotic lesions. 3. Patient has incomplete or missing data that does not allow for analysis. 4. Case reports (n<10 patients)

Study Design


Intervention

Device:
Viabahn implanted
An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.

Locations

Country Name City State
Netherlands Rijnstate Arnhem

Sponsors (1)

Lead Sponsor Collaborator
Rijnstate Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary patency Primary patency is defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-coded duplex sonography (CDUS, PSVR < 2.5) or no angiographic evidence of stenosis > 50% if CDUS is uninterpretable or unavailable. at 12 months.
Secondary Primary patency Primary patency is defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-coded duplex sonography (CDUS, PSVR < 2.5) or no angiographic evidence of stenosis > 50% if CDUS is uninterpretable or unavailable. at 24 months
Secondary Primary assisted patency Primary assisted patency is defined as flow through the treated lesion with or without repeat percutaneous intervention completed prior to complete vessel occlusion. 12 and 24 months
Secondary Secondary patency Secondary patency is defined as patency in the target lesion maintained by repeat intervention after complete occlusion of the treated arterial segment. 12 and 24 months
Secondary Freedom from Target Lesion Revascularization (TLR) Freedom from revascularization of the treated lesion after either restenosis or occlusion by means of a percutaneous vascular intervention, surgical by-pass, thrombolysis, or other such invasive means. 12 and 24 months
Secondary Clinical Improvement Clinical improvement is defined as at least one-group improvement in Rutherford Classification compared to baseline. 12 and 24 months
Secondary Major amputation Surgical removal of a portion of the study limb (generally above the ankle, transmetatarsal, or metatarsal) 12 and 24 months
Secondary Mortality Death, overall and procedure-related (until 30 days) 12 and 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT00536796 - Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets N/A
Completed NCT00371371 - Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI) Phase 1/Phase 2
Recruiting NCT00173602 - The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients N/A
Completed NCT00163267 - Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel Phase 2/Phase 3
Completed NCT00228384 - GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study Phase 4
Completed NCT00106327 - Improving Functioning in Peripheral Arterial Disease N/A
Completed NCT00049907 - Cardiac and Renal Disease Study (CARDS) N/A
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Completed NCT00005392 - Epidemiology of Venous Disease N/A
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Recruiting NCT00539266 - Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia Phase 2/Phase 3
Completed NCT00520312 - Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease N/A
Completed NCT00541307 - GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER) N/A
Terminated NCT00504088 - Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Phase 4
Completed NCT00533104 - Cell Therapy in Chronic Limb Ischemia Phase 1/Phase 2
Completed NCT03875846 - Intraoperative Simultaneous Pressure Guided Revascularization Study
Active, not recruiting NCT05110677 - Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images
Active, not recruiting NCT02856230 - An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK) Phase 2/Phase 3
Completed NCT01014377 - Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia N/A